Cited by 231Schizophrenia research and treatmentBipolar Disorder and TreatmentMental Health and Psychiatry

The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.

Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse

Moncrieff, J.·2006·Acta Psychiatrica Scandinavica

DOI 10.1111/j.1600-0447.2006.00787.x

Open this paper in CoChat — free account

Abstract

Objective: To examine the evidence that discontinuation of long‐term antipsychotic medication, including clozapine, may provoke a psychotic episode. Method: Databases were searched and citations scrutinised. Results: Evidence for a rapid onset psychosis (supersensitivity psychosis) following clozapine withdrawal was found and weaker evidence that this might occur with some other antipsychotic drugs. Some cases were reported in people without a psychiatric history. It appears that the psychosis may be a feature of drug withdrawal rather than the re‐emergence of an underlying illness, at least in some patients. Meta‐analyses of withdrawal studies have suggested that antipsychotic discontinuation may also increase the risk of relapse over and above the risk because of the underlying disorder, but not all individual studies show this effect. Mechanisms may relate to brain adaptations to long‐term drug use but data are sparse. Conclusion: These effects require further urgent research. Interventions to reduce morbidity after drug withdrawal need to be developed.

Integrity signals

Registry

Crossref · 10.1111/j.1600-0447.2006.00787.x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study
Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301
Dopaminergic supersensitivity after neuroleptics: time-course and specificity
Muller, P., & Seeman, P. (1978) · Psychopharmacology · doi:10.1007/bf00429171 · Cited by 271
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246 · cited 7×
“Dopamine receptor supersensitivity has been suggested as one such possible adaptation (48).”
BackgroundInfluential
Rapid Release of Antipsychotic Drugs From Dopamine D2 Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 216
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 194

Show all 64 references

Research works printed but not linked: 2

Franks MA, 2005, The consequences of suddenly stopping psychotropic medication in bipolar disorder, Bipolar Disorders, 4, 11
10.1345/aph.1A440 · DOI · Paper page

Sorted by citations

The nature of relapse in schizophrenia
Emsley, R. A., Chiliza, B., Asmal, L., & Harvey, B. H. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-50 · Cited by 481
Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders: A Systematic Overview of Meta-analyses
Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 293
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244
Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders
Larson, M. K., Walker, E. F., & Compton, M. T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.93 · Cited by 203
Maintenance treatment with antipsychotic drugs for schizophrenia
Ceraso, A., Lin, J., Schneider‐Thoma, J., Siafis, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Davis, J. M., & Leucht, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub3 · Cited by 184
Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Systematic Review of Clozapine Cardiotoxicity
Curto, M., Girardi, N., Lionetto, L., Ciavarella, G. M., Ferracuti, S., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0704-3 · Cited by 132
Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Review of withdrawal catatonia: what does this reveal about clozapine?
Lander, M., Bastiampillai, T. J., & Sareen, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0192-9 · Cited by 109
Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery?
Harrow, M., & Jobe, T. H. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt034 · Cited by 106
Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
Yin, J., Barr, A. M., Ramos‐Miguel, A., & Procyshyn, R. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160606093602 · Cited by 99
Mistakes I Have Made in My Research Career
Murray, R. M. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw165 · Cited by 93
Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia
Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.021 · Cited by 81
Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review
Sheehan, R., & Hassiotis, A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30191-2 · Cited by 81
Antipsychotic maintenance treatment: time to rethink
Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80
The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 81
Binding of clozapine to the GABAB receptor: clinical and structural insights
Nair, P. C., McKinnon, R. A., Miners, J. O., & Bastiampillai, T. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0709-5 · Cited by 76
Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 80
Prior Antipsychotic Drug Treatment Prevents Response to Novel Antipsychotic Agent in the Methylazoxymethanol Acetate Model of Schizophrenia
Gill, K. M., Cook, J. M., Poe, M. M., & Grace, A. A. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt236 · Cited by 74
Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
Oda, Y., Kanahara, N., & Iyo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226228 · Cited by 74
“Extended” Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia
Remington, G. J., Seeman, P. M., Feingold, A., Mann, S. W., Shammi, C., & Kapur, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05866yel · Cited by 65
The evidence-based practice of psychotherapy: Facing the challenges that lie ahead
Gaudiano, B. A., & Miller, I. W. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.04.004 · Cited by 73
Antipsychotic Dosing: How Much but also How Often?
Remington, G., & Kapur, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq083 · Cited by 65
Why is it so difficult to stop psychiatric drug treatment?
Moncrieff, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.009 · Cited by 59
Self-citation
Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients
Moritz, S., Hocaoglu, C., Karow, A., Deljković, A., Tonn, P., & Naber, D. (2009) · Mental Illness · doi:10.4081/mi.2009.e2 · Cited by 58
A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis
Fallon, P., & Dursun, S. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109359097 · Cited by 56
Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: A systematic review
Cooper, R. E., Laxhman, N., Crellin, N. E., Moncrieff, J., & Priebe, S. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.020 · Cited by 62
Self-citation
A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis
Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.022 · Cited by 55
Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
Takase, M., Kanahara, N., Oda, Y., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115570083 · Cited by 54
Clozapine discontinuation withdrawal symptoms in schizophrenia
Blackman, G., & Oloyede, E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032053 · Cited by 54
Clozapine and GABA transmission in schizophrenia disease models
O'Connor, W. T., & O’Shea, S. D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.005 · Cited by 58
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 53
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 52
Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study
Shah, P., Iwata, Y., Brown, E. E., Kim, J., Sanches, M., Takeuchi, H., Nakajima, S., Hahn, M., Remington, G. J., Gerretsen, P., et al. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01053-6 · Cited by 53
Frontale Hirnvolumenminderung durch Antipsychotika?
Aderhold, V., Weinmann, S., Hägele, C., & Heinz, A. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4027-5 · Cited by 52
Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
Blackman, G., Oloyede, E., Horowitz, M. A., Harland, R., Taylor, D. M., MacCabe, J. H., & McGuire, P. K. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 49
Psychotic relapse and associated factors among patients attending health services in Southwest Ethiopia: a cross-sectional study
Fikreyesus, M., Soboka, M., & Feyissa, G. T. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1076-2 · Cited by 48
Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis
Geyt, G. L., Awenat, Y. F., Tai, S., & Haddock, G. (2016) · Qualitative Health Research · doi:10.1177/1049732316634047 · Cited by 47
Antipsychotic-evoked dopamine supersensitivity
Servonnet, A., & Samaha, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.007 · Cited by 47
Nonadherence to antipsychotics: The role of positive attitudes towards positive symptoms
Moritz, S., Hünsche, A., & Lincoln, T. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.09.008 · Cited by 45
Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review
Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., Hetrick, S., Realpe, A., Vail, L., Dawson, S., & Sullivan, S. A. (2018) · BJPsych Open · doi:10.1192/bjo.2018.17 · Cited by 44
Re-Visioning Psychiatry
Kirmayer, L. J. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139424745.027 · Cited by 46
An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03822-5 · Cited by 44
Self-citation
Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder
Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder
Takeuchi, H., & Remington, G. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3154-1 · Cited by 44
Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications
van Wieringen, J., Booij, J., Shalgunov, V., Elsinga, P., & Michel, M. (2012) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-012-0817-0 · Cited by 40
Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
Huhn, M., Leucht, C., Rothe, P., Dold, M., Heres, S., Bornschein, S., Schneider-Axmann, T., Hasan, A., & Leucht, S. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01109-y · Cited by 38
A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43
Okada, M., Fukuyama, K., Shiroyama, T., & Murata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197019 · Cited by 39
The neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 38
Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia
Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., de Millas, W., Maier, W., Ruhrmann, S., Falkai, P., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.024 · Cited by 36
Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity
Kruyer, A., Parrilla-Carrero, J., Powell, C., Brandt, L., Gutwinski, S., Angelis, A., Chalhoub, R., Jhou, T. C., Kalivas, P. W., & Amato, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01235-6 · Cited by 37
Deprescribing antipsychotics: a guide for clinicians
Gupta, S., Cahill, J. D., & Miller, R. (2018) · BJPsych Advances · doi:10.1192/bja.2018.2 · Cited by 35
Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence
Emsley, R. A., Nuamah, I. F., Gopal, S., Hough, D. W., & Fleischhacker, W. W. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11874 · Cited by 34
Clonazepam Withdrawal-Induced Catatonia
Brown, M., & Freeman, S. A. (2009) · Psychosomatics · doi:10.1176/appi.psy.50.3.289 · Cited by 34
Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia
Roy-Desruisseaux, J., Landry, J., Bocti, C., Tessier, D., Hottin, P., & Trudel, J.-F. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q214 · Cited by 32
A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia
Takeuchi, H., Suzuki, T., Uchida, H., Nakajima, S., Nomura, K., Kikuchi, T., Manki, H., Watanabe, K., & Kashima, H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181842586 · Cited by 33
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33
Could cannabidiol be used as an alternative to antipsychotics?
Fakhoury, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.05.013 · Cited by 33
Do antipsychotic drugs lose their efficacy for relapse prevention over time?
Leucht, S., & Davis, J. M. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.117.201103 · Cited by 30
Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis
Yamanaka, H., Kanahara, N., Suzuki, T., Takase, M., Moriyama, T., Watanabe, H., Hirata, T., Asano, M., & Iyo, M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.013 · Cited by 29
The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
Fountoulakis, K. Ν., Moeller, H.-J., Kasper, S. F., Tamminga, C. A., Yamawaki, S., Kahn, R. S., Tandon, R., Correll, C. U., & Javed, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920001546 · Cited by 28
Aripiprazole in combination with other antipsychotic drugs may worsen psychosis
Adán-Manes, J., & García-Parajuá, P. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00996.x · Cited by 28
Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up
Kimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116655978 · Cited by 26
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
Brasso, C., Bellino, S., Bozzatello, P., Montemagni, C., & Rocca, P. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150568 · Cited by 27
Attempting to discontinue antipsychotic medication: Withdrawal methods, relapse and success
Larsen-Barr, M., Seymour, F. W., Read, J., & Gibson, K. L. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.001 · Cited by 27
Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia
Hutton, P., Morrison, A. P., Yung, A. R., Taylor, P. J., French, P., & Dunn, G. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01858.x · Cited by 26
The experiences of 585 people when they tried to withdraw from antipsychotic drugs
Read, J. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100421 · Cited by 27
Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis
Nieman, D. H., Rike, W. H., Becker, H. E., Dingemans, P. M. A. J., van Amelsvoort, T., de Haan, L., van der Gaag, M., Denys, D. A. J. P., & LINSZEN, D. H. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e0a76 · Cited by 24
Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders
Wunderink, L. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319836566 · Cited by 24
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats
Amada, N., Akazawa, H., Ohgi, Y., Maeda, K., Sugino, H., Kurahashi, N., Kikuchi, T., & Futamura, T. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12076 · Cited by 24
Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting
van Rossum, I., Tenback, D. E., & van Os, J. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-16 · Cited by 23
Explaining Attitudes and Adherence to Antipsychotic Medication: The Development of a Process Model
Wiesjahn, M., Jung, E., Lamster, F., Rief, W., & Lincoln, T. M. (2014) · Schizophrenia Research and Treatment · doi:10.1155/2014/341545 · Cited by 23
Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia
Nakata, Y., Kanahara, N., Kimura, H., Watanabe, H., & Iyo, M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000160 · Cited by 24
Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles
Horowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 22
Self-citation
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4247-2 · Cited by 23
Impairment of left ventricular function early in treatment with clozapine
Curto, M., Comparelli, A., Ciavarella, G. M., Gasperoni, C., Lionetto, L., Corigliano, V., Uccellini, A., Mancinelli, I., Ferracuti, S., Girardi, P., et al. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000085 · Cited by 23
Transient psychosis in women on clomiphene, bromocriptine, domperidone and related endocrine drugs
Seeman, M. V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1060957 · Cited by 22
Drug Approval and Drug Effectiveness
Spielmans, G. I., & Kirsch, I. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185533 · Cited by 21
Addressing non‐adherence to antipsychotic medication: a harm‐reduction approach
ALDRIDGE, M. A. (2011) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2011.01809.x · Cited by 21
Powerful Choices: Peer Support and Individualized Medication Self-Determination
West, C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp053 · Cited by 21
At-risk mental state for psychosis: identification and current treatment approaches
Thompson, A. D., Marwaha, S., & Broome, M. R. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.015487 · Cited by 21
First, do no harm: Confronting the myths of psychiatric drugs
Barker, P., & Buchanan‐Barker, P. (2012) · Nursing Ethics · doi:10.1177/0969733011429017 · Cited by 20
Raising Adults as Children? A Report on Milieu Therapy in a Psychiatric Ward in Norway
Oeye, C., Bjelland, A. K., Skorpen, A., & Anderssen, N. (2009) · Issues in Mental Health Nursing · doi:10.1080/01612840802557246 · Cited by 20
Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data
Bobo, W. V., Stovall, J., Knostman, M., Koestner, J., & Shelton, R. C. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080595 · Cited by 19
G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis
Oda, Y., Tadokoro, S., Takase, M., Kanahara, N., Watanabe, H., Shirayama, Y., Hashimoto, K., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115593903 · Cited by 19
A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine
Sherwood, M., Thornton, A. E., & Honer, W. G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440513 · Cited by 17
Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies
Stip, É., Zhornitsky, S., Potvin, S., & Tourjman, V. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.010 · Cited by 17
Iatrogenia y prevención cuaternaria en salud mental
Lobo, A. O., & Rojo, V. (2011) · Revista Española de Salud Pública · doi:10.1590/s1135-57272011000600002 · Cited by 19
Recurrent clozapine and lorazepam withdrawal psychosis with catatonia
Wang, B. Z., Gupta, A., Bastiampillai, T. J., & Sani, F. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412444992 · Cited by 17
Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis
Tachibana, M., Niitsu, T., Watanabe, M., Hashimoto, T., Kanahara, N., Ishikawa, M., & Iyo, M. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.014 · Cited by 17
New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base
Ostuzzi, G., Papola, D., Gastaldon, C., & Barbui, C. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016001025 · Cited by 17
Effect of Citalopram in Combination with Omega-3 on Depression in Post- menopausal Women: A Triple Blind Randomized Controlled Trial
Masoumi, S. Z. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19487.8597 · Cited by 17

Authors: Moncrieff, J.
Affiliations: University College London (GB)
Corresponding author: Moncrieff, J.
ORCID: Moncrieff, J.
Venue: Acta Psychiatrica Scandinavica
Publisher: Wiley
Published: 2006-03-23
Volume: 114
Issue: 1
Pages: 3-13
ISSN: 0001-690X (ISSN-L)
1600-0447
DOI: 10.1111/j.1600-0447.2006.00787.x
OpenAlex: W2168608597
Cited by: 231
References: 64
Citations by year: 2026: 5 · 2025: 5 · 2024: 8 · 2023: 8 · 2022: 10 · 2021: 23 · 2020: 14 · 2019: 13 · 2018: 10 · 2017: 8 · 2016: 18 · 2015: 19 · 2014: 13 · 2013: 14 · 2012: 11
FWCI: 1.38
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Acta Psychiatrica Scandinavica (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: antipsychotic withdrawal, clozapine, antipsychotic discontinuation, psychosis relapse, drug withdrawal
MeSH terms: Clozapine, Humans, Long-Term Care, Psychoses, Substance-Induced, Psychotic Disorders, Recurrence, Risk Factors, Substance Withdrawal Syndrome, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks